Navigation Links
Mayo Clinic: How patients will respond to immunomodulator therapy for multiple myeloma
Date:12/11/2011

SAN DIEGO -- Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of Mayo Clinic in Arizona. Dr. Stewart presented the results at the 53rd annual meeting of the American Society of Hematology in San Diego.

The drug thalidomide achieved infamy in the early 1960s as the cause of severe birth defects after being given to pregnant mothers for morning sickness. However, this drug, along with the highly related compounds lenalidomide and pomalidomide, also help to treat blood cancers, and are used worldwide as a cornerstone of therapy for the bone marrow cancer multiple myeloma. These drugs modulate the immune system and together are called immunomodulators or IMiDs.

The exact mechanisms and targets through which these therapies work to enhance immune response or kill cancer cells have been largely unknown. As a result, knowing which patients to treat and how to separate out the positive properties of these drugs from side effects has been impossible.

After recent research identified a protein known as cereblon as a primary mediator of the birth defects caused by thalidomide, researchers theorized that cereblon may also orchestrate the anti-tumor properties and be the primary therapeutic target for multiple myeloma.

In this study, researchers tested the theory and found a possible link between resistance to IMiDs and presence of cereblon. The researchers then found that lowering the level of cereblon allows the IMiDs to work properly.

"Interestingly, some resistant patients had normal cereblon levels, suggesting that while cereblon may be an absolute requirement for response, there are likely other mechanisms present that play a role in drug resistance," says Dr. Stewart. "These findings help us understand which patients may be more or less likely to respond to therapy and allow us to focus on other ways we can target cereblon as a possible biomarker to improve treatment and patient outcomes in multiple myeloma. This work also suggests that we can begin to dissect out the cause of birth defects from the anti-cancer properties and develop safer drugs in the future."


'/>"/>

Contact: Joe Dangor
dangor.yusuf@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility
2. Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award
3. Mayo Clinic: Flaxseed no cure for hot flashes during breast cancer or menopause
4. Mayo Clinic: Primary physicians may hold key to suicide prevention
5. Mayo Clinic: Short training course significantly improves detection of precancerous polyps
6. Mayo Clinic: Young women with rheumatoid arthritis at more risk for broken bones
7. Mayo Clinic: Obese patients with HER2-positive breast cancer may have worse outcomes
8. ICU Patients at Risk for Rare Heart Rhythm Problem
9. Young patients with chronic illnesses find relief in acupuncture
10. For Some Breast Cancer Patients, Shorter Radiation Works Well
11. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... Digital Scientists, a software innovation lab specializing in web ... Greenville, South Carolina location. The lab has set up shop at the ... working with South Carolina clients for years from our office here in Atlanta,” explains ...
(Date:3/24/2017)... ... 2017 , ... According to a new study by NCPA Senior Fellow John ... the rules Congress has directed the CBO to follow. The CBO itself previously recognized ... Yet, it estimates a reduction in employer-based coverage due to the GOP reform, which ...
(Date:3/24/2017)... ... 24, 2017 , ... The iaedp Foundation, the premier provider of educational programs ... suffering from the full spectrum of disordered eating, announced today that the 2017 Symposium ... all 50 states and several countries converged on the Green Valley Resort in Las ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred ... 2017. This sacred and spiritual journey during the Summer Solstice will also ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017 Today Stock-Callers.com have issued research ... Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences ... SSH ). These companies are part of the Healthcare sector, ... March 23 rd , 2017, with the NYSE Health Care ... care companies in the S&P 500 were down about 0.4% ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
Breaking Medicine Technology: